OTS - Series A financing round lays foundation for international growth of digital cancer therapeutics Mika (part 1)
2022. May 09. 11:48
Berlin/Lausanne/Barcelona/Munich, 9 May, 2022 (APA/OTS) - New
investors with a successful track record in digital oncology
support German Digital Therapeutics (DTx) company Fosanis to
broaden patient access of Mika - an app-based DTx platform
empowering people affected by cancer. - Berlin-based digital health
company Fosanis, the developer of Mika, Germany's first
prescription DTx for all oncological indications, closed a series A
funding round of more than 10 million EUR. Besides existing
shareholders such as Ananda Impact Ventures, three new investors
joined in the latest financing round: lead investor Swiss company
Debiopharm Innovation Fund, Ship2B Ventures from Spain and venture
capital firm Equity Pitcher.
As digital therapeutics gain momentum on a worldwide scale,
Germany has pioneered the digital therapeutics regulation. Mika has
emerged as the leading oncological DTx platform in Germany in
recent years proving its value to cancer patients and the
healthcare system in clinical trials. The personalised platform
delivers evidence-based digital interventions with a view to
supporting cancer patients in coping with the challenges of the
disease and treatment process.
According to the World Health Organization (WHO), approximately
19.3 million people are diagnosed with cancer worldwide. "Cancer
knows no boundaries. Helping people affected by cancer shouldn't
either", says Mika Founder and Managing Director Dr Jan Simon Raue.
"We have developed Mika to bring back some of the control when
guidance and support is most needed: from diagnosis all the way
through the therapy process. Our mission is to empower everyone
affected by cancer. Knowing that every cancer patient is a human
being with individual needs, Mika provides personalised and
comprehensive cancer therapy support, combining the latest insights
in cancer research with 24/7 hands-on help wrapped up in an
easy-to-handle and engaging digital tool."
The capital raised in this series A round will support Mika's
expansion into international terrain. While Fosanis reveals its
plan to enter the UK healthcare ecosystem still in 2022, it also
wants to partner with renowned international cancer research
centres to conduct even more studies on the medical impact of
AI-driven personalisation in digital interventions. Mika Co-Founder
and Managing Director Dr Gandolf Finke:
"The importance of digital health and digital therapeutics in
particular is growing globally. This financing round marks an
important milestone in our company history, allowing us to scale
our oncology DTx platform and position our offerings
internationally. We welcome our new investors on board and look
forward to working closely with them to take Mika to new heights."
Debiopharm is an experienced investor in the digital health
domain with a special focus on cancer. Tanja Dowe, CEO of
Debiopharm Innovation Fund: "We are convinced that digital
solutions can fill many critical gaps in healthcare and, especially
with regards to cancer therapy support, provide tremendous relieve
for patients and attending physicians alike. Mika promotes patient
empowerment and enables those affected to cope with their disease
and therapy, independent of time and location. For this very
reason, we do not only think of ourselves as mere investors, but we
also support the company in strategy and execution and are proud to
accompany Mika's further growth."
Ship2B, based in Barcelona, invests primarily in start-ups that
have the potential to make a worthwhile and lasting contribution to
the world. Impact, i.e., the aspiration to make a real change, is
at the forefront of their thinking, as Maite Fibla, Co-Founder and
Managing Partner of Ship2B, points out: "We are proud to contribute
to the internationalization of Mika, which means being able to
improve the quality of life of many more cancer patients. Not only
does its mission meet our parameters of what an impact start-up
should be, but we have felt fully committed to it. It seems
especially significant to us to think that, thanks to what was
achieved in the round, there may be the possibility of giving
Spain, among other countries, this innovative proposal in
oncological therapies."
Andrea Buhofer, Partner at EquityPitcher Ventures, moreover
highlights the growing importance of patient-centric solutions in
integrative digital oncology: "Personalized, digital and accessible
support in cancer therapy is becoming increasingly important. Mika
has developed an extremely user-friendly application with in-demand
content, and we are very pleased to have been able to support Mika
in continuing to grow and make therapy support available to more
people."
Alongside the new investors, current shareholders contributed
to the funding round, led by impact VC Ananda Impact Ventures and
several business angels who had already joined Mika's mission in a
previous seed investment round. Dr Bernd Klosterkemper, Partner at
Ananda Impact Ventures, explains: "We are a home for entrepreneurs
who tackle the pressing challenges of our time in a scalable way.
From the very beginning, Mika has been aspiring to create a
positive impact on the well-being and quality of life of cancer
patients. As its meaningful vision deeply resonates with our
ambition to back game-changing and purpose-driven solutions, we are
very much looking forward to cementing ties and helping Mika
achieve global impact." (continues)